A postdoctoral position is now available and funded for three years at the Ludwig Institute for Cancer Research (Lausanne, Switzerland) to study anti-tumoral T-cell mediated responses in well-defined clinical situations and identify key biological determinants related to clinical efficiency. The Rufer lab is working on T-cell responses against tumour antigens in cancer patients following therapeutic vaccination or undergoing checkpoint blockade therapies, as well as on long-lasting T cell memory responses for herpes viruses in healthy donors. We recently showed that the T cell receptor (TCR)-binding avidity is highly informative for assessing antigen-specific T cell responses and represents a strong candidate as a biomarker of T cell therapeutic efficacy (1, 2).We are also investigating on approaches to optimise the TCR binding avidity for tumour antigens, with the aim to understand how anti-cancer T cells sense the differences in TCR-peptide-MHC binding interactions (3). Our work contributes to advance our knowledge of T-cell mediated protection from human diseaseand guides the rational development of T cell-based therapies.
The postdoctoral fellow will have the unique opportunity to work in the recently integrated multidisciplinary Swiss Cancer Center at Lausanne (SCCL), focusing on cancer, genetics and immunology, and strengthened by the scientific and clinical expertise of the Ludwig Institute for Cancer Research (LICR), the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL) and the Swiss Federal Institute of Technology of Lausanne (EPFL). The SCCL also offers many core facilities as well as a highly dynamic and international working environment.
Eligible candidates should hold a PhD or an MD/PhD in immunology, cancer biology or biochemistry with strong background in human T-cell biology. They must have solid expertise in immunology or oncology, including cellular & molecular biology. Applicants should send a cover letter, including a brief statement of research experience and interests (max 2 pages), their curriculum vitae and publication list, as well as the names and contact information of three references by e-mail to:
Dr. Nathalie Rufer, PhD, MD
Lausanne University Hospital and University of Lausanne
Ludwig Institute of Cancer Research
E-mail : firstname.lastname@example.org
Relevant literature :
- Allard M et al. TCR-ligand dissociation rate is a robust and stable biomarker of CD8 T cell potency. JCI Insight. 2(14). 2017
- Hebeisen M et al. Identification of rare high avidity tumor reactive CD8 T cells by monomeric TCR-ligand off-rate measurements on living cells. Cancer Res. 75(10):1983. 2015
- Presotto D et al. Fine-tuning of optimal TCR signaling in tumor-redirected CD8 T cells by distinct TCR affinity-mediated mechanisms. Front Immunol. 15(8):1564. 2017